• ABCL is trading at $8.52 (+4.93%) in pre-market, continuing a strong multi-day rally.
  • The stock's momentum is driven by its recent preclinical research, option, and license collaboration with Jazz Pharmaceuticals, announced on June 17, 2026.
  • The deal includes $56 million upfront, potential additional funding of $28 million, and up to $792 million per program in milestones plus royalties.